Report cover image

Lymphoma Therapeutics Market by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), End User (Ambulatory Surgical Centers, Clinics, Hospitals) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 182 Pages
SKU # IRE18445658

Description

Lymphoma Therapeutics Market by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), End User (Ambulatory Surgical Centers, Clinics, Hospitals) - Global Forecast 2024-2030


The Lymphoma Therapeutics Market size was estimated at USD 9.23 billion in 2023 and expected to reach USD 10.50 billion in 2024, at a CAGR 14.18% to reach USD 23.37 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lymphoma Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lymphoma Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lymphoma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Accredo Health, Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Lymphoma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment

Chemotherapy

Immunotherapy
Chimeric Antigen Receptor T-Cell Therapy
Immune Checkpoint Inhibitors
Monoclonal Antibodies

Radiation Therapy

Stem Cell or Bone Marrow Transplantation

Surgery

Targeted Therapy
End User

Ambulatory Surgical Centers

Clinics

Hospitals
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Lymphoma Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lymphoma Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Lymphoma Therapeutics Market?
4. What is the market share of the leading vendors in the Lymphoma Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Lymphoma Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

182 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Lymphoma Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of different types of cancer
5.1.1.2. Increasing adoption of premium products such as immune checkpoint inhibitors and Keytruda
5.1.1.3. Recent approval of several novel therapies
5.1.2. Restraints
5.1.2.1. High cost of therapies
5.1.3. Opportunities
5.1.3.1. Increasing co-promotion and commercialization
5.1.3.2. Extensive growth in R&D practices
5.1.4. Challenges
5.1.4.1. Patent expiry of drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Lymphoma Therapeutics Market, by Treatment
6.1. Introduction
6.2. Chemotherapy
6.3. Immunotherapy
6.4.1. Chimeric Antigen Receptor T-Cell Therapy
6.4.2. Immune Checkpoint Inhibitors
6.4.3. Monoclonal Antibodies
6.4. Radiation Therapy
6.5. Stem Cell or Bone Marrow Transplantation
6.6. Surgery
6.7. Targeted Therapy
7. Lymphoma Therapeutics Market, by End User
7.1. Introduction
7.2. Ambulatory Surgical Centers
7.3. Clinics
7.4. Hospitals
8. Americas Lymphoma Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Lymphoma Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Lymphoma Therapeutics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Accredo Health, Inc.
12.1.2. Amgen Inc.
12.1.3. Bristol-Myers Squibb Company
12.1.4. Eli Lilly and Company
12.1.5. F. Hoffmann-La Roche Ltd.
12.1.6. Gilead Sciences, Inc.
12.1.7. GlaxoSmithKline PLC
12.1.8. Johnson & Johnson Services, Inc.
12.1.9. Merck & Co., Inc.
12.1.10. Novartis AG
12.1.11. Pfizer Inc.
12.1.12. Seagen Inc.
12.1.13. Spectrum Pharmaceuticals, Inc.
12.1.14. Takeda Pharmaceutical Company
12.1.15. Teva Pharmaceutical Industries Ltd.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. LYMPHOMA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. LYMPHOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. LYMPHOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. LYMPHOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. LYMPHOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LYMPHOMA THERAPEUTICS MARKET DYNAMICS
FIGURE 7. LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 8. LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 10. LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. LYMPHOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. LYMPHOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us